Schizophrenia Research: from Epidemiological Trends to Experimental Models, in Vitro Studies, and Emerging Treatments

Abstract

Schizophrenia is a severe mental illness affecting over 21 million individuals worldwide, leading to cognitive, social, and emotional impairments. It is characterized by positive symptoms (hallucinations, delusions), negative symptoms (anhedonia, avolition), and cognitive deficits. While traditionally viewed as a distinct disorder, emerging perspectives suggest schizophrenia exists on a psychosis spectrum. The condition has strong genetic links, with environmental factors such as fetal development issues, urban residence, and cannabis use increasing risk. Neurotransmitter imbalances, particularly in dopamine, serotonin, and glutamate pathways, contribute to its pathophysiology. Treatment strategies primarily rely on antipsychotic medications, but one-third of patients exhibit treatment resistance. Clozapine remains the standard for refractory cases, while psychosocial interventions improve long-term outcomes. Emerging treatments include novel pharmacologic agents like TAAR-1 agonists, transdermal asenapine, and long-acting injectables, targeting cognition, negative symptoms, and adherence issues. Despite advancements, schizophrenia remains a complex and multifaceted disorder, requiring continued research to improve therapeutic outcomes and quality of life for affected individuals.